Can a targeted radiation boost slow advanced lung cancer?
NCT ID NCT07135882
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung cancer that has spread to up to three organ systems will be randomly assigned to receive standard drug therapy alone or with upfront radiotherapy. The study will also look at side effects, quality of life, and cost-effectiveness to see if this combined approach is worth adopting widely.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiotherapy to the primary lung tumour, given alongside standard chemotherapy or immunotherapy
- What this could lead to
- If it works, adding radiotherapy to standard drug therapy could slow cancer spread, extend life, and improve well-being for people with metastatic lung cancer.
- What could go wrong
- This is a large phase III trial, but radiotherapy to the chest can cause side effects like inflammation or damage to nearby organs. It may not improve overall survival or quality of life for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 420 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2036
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newly diagnosed metastatic (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy * Histologically or cytologically documented NSCLC * EGFR/ALK/ROS1 Wild-type * Primary suitable for radiotherapy and not requiring immediate palliative thoracic irradiation * Investigator deemed appropriate for SoC systemic therapy * Metastases in up to 3 organ systems Exclusion Criteria: * Medically unfit for systemic therapy * EGFR/ALK/ROS1 mutation positive or actionable driver mutation with intention to use available targeted drug therapy * Has had previous thoracic radiotherapy of \> 36Gy within the 6 months prior to randomisation. * Has been diagnosed and/or treated additional malignancy within 2 years prior to randomisation with the exception of: Curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively treated early-stage cervical cancer, breast cancer or prostate cancer with no evidence of active disease and not on active therapy. Other exceptions may be considered following consultation with the principal investigator * Has a history of (non-infectious) pneumonitis or current pneumonitis that requires active corticosteroids with a dose equivalent of prednisolone \> 10mg/d. * A known diagnosis of fibrotic interstitial lung disease * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Uncontrolled brain metastasis not amenable to debulking surgery or stereotactic radiotherapy * Has an active autoimmune disease that has required systemic treatment within last year (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ICON Cancer Centre - Gold Coast University Hospital
Gold Coast, Queensland, 4215, Australia
-
Peter MacCallam Cancer Centre
Melbourne, Victoria, 3000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antidepressant may ease brain fog from lung cancer drug
- PET scans may reveal early if immunotherapy works for lung cancer
- Can simulated High-Altitude breathing boost lung cancer treatment?
- New drug cocktail shows promise in shrinking lung tumors before surgery
- New lung cancer drug shows promise in early trial
- New drug combo aims to boost lung cancer treatment